Shareholders of GSK plc Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – GSK
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: GlobeNewswire
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=139445&from=3 CLASS PERIOD: February 5, 2020 to August 14, 2022 ALLEGATIONS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association b
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSKPR Newswire
- Exdensur (depemokimab) approved by US FDA for the treatment of severe asthmaBusiness Wire
- GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) had its "reduce" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
GSK
Sec Filings
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- 12/19/25 - Form 6-K
- GSK's page on the SEC website